SERUM LEVELS OF CYTOKINES AND SECONDARY MESSAGES AFTER T-CELL-DEPLETED AND NON-T-CELL-DEPLETED BONE-MARROW TRANSPLANTATION - INFLUENCE OF CONDITIONING AND HEMATOPOIETIC RECONSTITUTION
H. Schwaighofer et al., SERUM LEVELS OF CYTOKINES AND SECONDARY MESSAGES AFTER T-CELL-DEPLETED AND NON-T-CELL-DEPLETED BONE-MARROW TRANSPLANTATION - INFLUENCE OF CONDITIONING AND HEMATOPOIETIC RECONSTITUTION, Transplantation, 62(7), 1996, pp. 947-953
Cytokines are increasingly recognized as important mediators of graft-
versus-host disease (GVHD), Measurements of cytokine serum levels in p
atients with GVHD, and successful prevention and treatment of the dise
ase with the use of cytokine antagonists to either the cytokine or its
receptor, are only two of several factors demonstrating the involveme
nt of cytokines in GVHD, To further investigate the role of cytokines
in the pathomechanism of acute GVHD, we investigated endogenous serum
levels of various cytokines and dependent molecules in sera of 14 pati
ents after T-cell-depleted (TCD) bone marrow transplantation (BMT) and
compared the results with those of 12 patients undergoing non-TCD BMT
, The effect of various conditioning regimens and of hematopoietic rec
onstitution on cytokine serum levels was analyzed in detail in these c
ohorts of patients by measuring interferon (IFN)-gamma, IFN-alpha, tum
or necrosis factor-alpha, interleukin-6, neopterin, and beta 2-microgl
obulin, The analyses showed that an increase in IFN-gamma and neopteri
n serum levels was a specific feature of cyclophosphamide administrati
on and was not observed after other cytostatic drugs or total body irr
adiation, and that an increase in IFN-gamma, neopterin, beta 2-microgl
obulin, and IFN-alpha release depends on the presence of T cells in th
e graft. We conclude that significant cytokine serum alterations were
noted after TCD BMT as compared with after non-TCD BMT. These alterati
ons, besides depletion of cytotoxic effector cells, might be involved
in preventing GVHD after TCD BMT, In addition, more attention should b
e devoted to the cytokine release-inducing capacity of the conditionin
g regimen, because such a release might influence the occurrence of tr
ansplant related complications after BMT.